Previous 10 | Next 10 |
2023-06-21 16:57:40 ET Marinus Pharmaceuticals ( NASDAQ: MRNS ) said Wednesday that the United States Patent and Trademark Office has granted a new method of use patent for intravenous ganaxolone in the treatment of status epilepticus, expiring in 2040. The company said ...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a new method of use patent for intravenous (IV) gana...
2023-06-15 07:51:04 ET Mersana Therapeutics ( NASDAQ: MRSN ) lost ~60% pre-market Thursday after announcing that the FDA issued a partial clinical hold halting the enrollment in its UP-NEXT and UPGRADE-A trials for lead asset UpRi in platinum-sensitive ovarian cancer. The ...
2023-05-26 08:20:12 ET A committee of the European Medicines Agency (EMA) recommended the approval of Marinus Pharmaceuticals' ( NASDAQ: MRNS ) Ztalmy (ganaxolone) to treat epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder...
The European Commission decision is expected within 67 days of the CHMP opinion Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Committee for Medicinal...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors. “Sarah is an accomplished healthcare ...
2023-05-11 13:58:03 ET Marinus Pharmaceuticals, Inc. (MRNS) Q1 2023 Results Conference Call May 11, 2023 08:30 AM ET Company Participants Sasha Damouni Ellis - Vice President of Corporate Affairs and Investor Relations Scott Braunstein - Chairman and Chief Executive ...
2023-05-11 07:07:12 ET Marinus Pharmaceuticals press release ( NASDAQ: MRNS ): Q1 GAAP EPS of -$0.67 beats by $0.13 . Revenue of $10.38M (-26.8% Y/Y) beats by $5.47M . For the fiscal year 2023, the Company maintains its prior guidance with expected ZTALMY ...
ZTALMY ® (ganaxolone) first quarter U.S. net product revenue of $3.3 million Now planning to conduct an interim analysis for the Phase 3 refractory status epilepticus trial in the second half of 2023 CHMP opinion for ZTALMY in CDKL5 deficiency disorder expected by end of May; Eur...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2023 on May 11, 2023. The Company will host a...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...
Philadelphia, Pennsylvania--(Newsfile Corp. - July 15, 2024) - Attention Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) Investors. A securities fraud class action lawsuit has been filed against Marinus on behalf of purchasers of Marinus securities between March 17, 20...
RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not progressing to IV anesthesia...